Atlas FDA

Exablate Model 4000 Type-1 System

FDA premarket approval P150038/S037 · decided 2025-07-03

Approval details

PMA number
P150038
Supplement
S037
Supplement type
Panel Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
Exablate Model 4000 Type-1 System
Generic name
MR-guided focused ultrasound system
Applicant
Insightec
Date received
2024-07-16
Decision date
2025-07-03
Days to decision
352 days
Decision code
APPR
Product code
POH
Advisory committee
Neurology
Expedited review
No
Location
Tirat Carmel
Statement
The Exablate Neuro is intended indicated for use in the unilateral pallidothalamic tractotomy of advanced idiopathic Parkinson’s Disease with medication-refractory moderate to severe motor complications as an adjunct to Parkinson’s disease medication treatment, and in the staged (by at least 6 months from the first pallidothalamic tractotomy), unilateral pallidothalamic tractotomy of idiopathic Parkinson’s Disease with medication-refractory motor complications of their contralateral side that wa

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.